↓ Skip to main content

Dove Medical Press

Daily intake of rosehip extract decreases abdominal visceral fat in preobese subjects: a randomized, double-blind, placebo-controlled clinical trial

Overview of attention for article published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, March 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 1,184)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
32 news outlets
blogs
1 blog
twitter
16 X users
patent
1 patent
facebook
6 Facebook pages
reddit
1 Redditor
video
2 YouTube creators

Readers on

mendeley
87 Mendeley
Title
Daily intake of rosehip extract decreases abdominal visceral fat in preobese subjects: a randomized, double-blind, placebo-controlled clinical trial
Published in
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, March 2015
DOI 10.2147/dmso.s78623
Pubmed ID
Authors

Akifumi Nagatomo, Norihisa Nishida, Ikuo Fukuhara, Akira Noro, Yoshimichi Kozai, Hisao Sato, Yoichi Matsuura

Abstract

Obesity has become a great problem all over the world. We repeatedly screened to find an effective food to treat obesity and discovered that rosehip extract shows potent anti-obesity effects. Investigations in mice have demonstrated that rosehip extract inhibits body weight gain and decreases visceral fat. Thus, the present study examined the effect of rosehip extract on human body fat in preobese subjects. We conducted a 12-week, single-center, double-blind, randomized, placebo-controlled study of 32 subjects who had a body mass index of ≥25 but <30. The subjects were assigned to two random groups, and they received one tablet of placebo or rosehip that contained 100 mg of rosehip extract once each day for 12 weeks with no dietary intervention. Abdominal fat area and body fat percent were measured as primary outcomes. The other outcomes were body weight and body mass index. Abdominal total fat area, abdominal visceral fat area, body weight, and body mass index decreased significantly in the rosehip group at week 12 compared with their baseline levels (P<0.01) after receiving the rosehip tablet intake, and the decreases in these parameters were significantly higher when compared with those in the placebo group. Additionally, body fat percent tended to decrease compared with the placebo group and their baseline level. Moreover, the abdominal subcutaneous fat area was significantly lower in the rosehip group than in the placebo group at week 12 after the initiation of intake (P<0.05). In addition, there were no abnormalities, subjective symptoms, and findings that may indicate clinical problems during the study period. These results suggest that rosehip extract may be a good candidate food material for preventing obesity.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Unknown 86 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 20%
Student > Bachelor 11 13%
Student > Master 11 13%
Other 10 11%
Student > Ph. D. Student 6 7%
Other 8 9%
Unknown 24 28%
Readers by discipline Count As %
Agricultural and Biological Sciences 16 18%
Biochemistry, Genetics and Molecular Biology 13 15%
Medicine and Dentistry 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Nursing and Health Professions 4 5%
Other 11 13%
Unknown 29 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 273. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2024.
All research outputs
#131,679
of 25,457,858 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#5
of 1,184 outputs
Outputs of similar age
#1,390
of 271,183 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#1
of 10 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,183 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them